epidermal growth factor receptor

Showing 1 - 5 of 5

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Glioblastoma Multiforme, Glycolytic Index, Epidermal Growth Factor Receptor Trial (pH Measurement of in vivo tissue)

Not yet recruiting
  • Glioblastoma Multiforme
  • +2 more
  • pH Measurement of in vivo tissue
  • (no location specified)
Sep 26, 2023

NSCLC, Epidermal Growth Factor Receptor, Leptomeningeal Metastasis Trial (Pemetrexed)

Not yet recruiting
  • Carcinoma, Non-Small-Cell Lung
  • +2 more
  • (no location specified)
Mar 27, 2023

Recurrent Cervical Carcinoma, Radiotherapy, Epidermal Growth Factor Receptor Trial in Beijing (Combination of nimotuzumab and

Recruiting
  • Recurrent Cervical Carcinoma
  • +6 more
  • Combination of nimotuzumab and radiotherapy
  • Beijing, Beijing, China
    Lei Li
Dec 18, 2020

Epidermal Growth Factor Receptor, NSCLC Trial in Boston (Erlotinib)

Terminated
  • Epidermal Growth Factor Receptor
  • Non-Small Cell Lung Cancer
  • Boston, Massachusetts
  • +2 more
Nov 5, 2019

NSCLC, Epidermal Growth Factor Receptor Trial in Guangzhou (Erlotinib Hydrochloride)

Unknown status
  • Non-small Cell Lung Cancer
  • Epidermal Growth Factor Receptor
  • Erlotinib Hydrochloride
  • Guangzhou, Guangdong, China
    Guangdong General Hospital
Mar 5, 2017